Myriad Genetics, Inc. (MYGN) Market Cap & Valuation Ratios
Myriad Genetics, Inc. (MYGN) has a market cap of $556.7M and a price-to-sales ratio of 0.7, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MYGNMyriad Genetics, Inc.Follow MYGN — free
—
Price chart with a free account
- Market cap
- 556.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Peers
diagnostics & research · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| MYGN | 0.6 | — | 0.7 | — | -1.3% | -3% | -12% | -29% |
| CDNA | 3.6 | 33.4 | 7.0 | 26.2 | 1.0% | +34% | 24% | 67% |
| NEO | 2.1 | — | 3.1 | — | -0.3% | +11% | -9% | -7% |
| PSNL | 1.7 | — | 21.2 | — | -6.0% | -13% | -164% | -82% |
| WGS | 1.7 | — | 3.6 | — | -4.5% | +25% | -20% | -35% |
| OPK | 1.2 | — | 2.1 | 30.5 | -11.0% | -11% | -8% | -4% |
| LMRI | 1.1 | — | — | — | — | — | 9% | — |
| CSTL | 1.0 | — | 2.1 | — | -0.0% | +3% | -9% | -8% |
| FLGT | 0.6 | — | 0.9 | — | — | +7% | -38% | -12% |
| YDES | 0.4 | — | 280.8 | — | -2.5% | +17% | — | -362% |
| TKNO | 0.3 | — | 7.8 | — | -2.1% | +12% | -36% | -20% |
| Median of these 10 | 33.4 | 3.6 | 28.3 | -2.3% | +11% | -9% | -12% |
; EV/Sales 0.7 vs. 3.6.
Growth vs. price
each dot a company · hover or tap for valuesMyriad Genetics, Inc. — questions
- What is Myriad Genetics, Inc.'s market cap?
- $556.7M.
- What is Myriad Genetics, Inc.'s price-to-sales ratio?
- 0.7.
Every figure on this page comes from Myriad Genetics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.